ATE439139T1 - Bakteriophage zur behandlung von bakteriellen biofilmen - Google Patents

Bakteriophage zur behandlung von bakteriellen biofilmen

Info

Publication number
ATE439139T1
ATE439139T1 AT04701383T AT04701383T ATE439139T1 AT E439139 T1 ATE439139 T1 AT E439139T1 AT 04701383 T AT04701383 T AT 04701383T AT 04701383 T AT04701383 T AT 04701383T AT E439139 T1 ATE439139 T1 AT E439139T1
Authority
AT
Austria
Prior art keywords
bacteriophage
biofilm
treatment
bacterial biofilm
bacteriophages
Prior art date
Application number
AT04701383T
Other languages
English (en)
Inventor
Richard Sharp
Gavin Hughes
A Hart
James Taggart Walker
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Application granted granted Critical
Publication of ATE439139T1 publication Critical patent/ATE439139T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02003—Poly(beta-D-mannuronate) lyase (4.2.2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04701383T 2003-01-10 2004-01-12 Bakteriophage zur behandlung von bakteriellen biofilmen ATE439139T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0300597.2A GB0300597D0 (en) 2003-01-10 2003-01-10 Phage biofilms
PCT/GB2004/000073 WO2004062677A1 (en) 2003-01-10 2004-01-12 Bacteriophage for the treatment of bacterial biofilms

Publications (1)

Publication Number Publication Date
ATE439139T1 true ATE439139T1 (de) 2009-08-15

Family

ID=9950965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701383T ATE439139T1 (de) 2003-01-10 2004-01-12 Bakteriophage zur behandlung von bakteriellen biofilmen

Country Status (6)

Country Link
US (1) US7758856B2 (de)
EP (1) EP1587520B1 (de)
AT (1) ATE439139T1 (de)
DE (1) DE602004022506D1 (de)
GB (1) GB0300597D0 (de)
WO (1) WO2004062677A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004258731B2 (en) 2003-07-23 2010-02-25 Biocontrol Limited Bacteriophage-containing therapeutic agents
EP1791566A4 (de) * 2004-08-06 2008-07-16 Nat Jewish Med & Res Center Produkt und verfahren zur hemmung der biofilm-entwicklung
US8182804B1 (en) 2004-09-13 2012-05-22 Trustees Of Boston University Engineered enzymatically active bacteriophages and methods of uses thereof
WO2006095345A2 (en) 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
US7932029B1 (en) * 2006-01-04 2011-04-26 Si Lok Methods for nucleic acid mapping and identification of fine-structural-variations in nucleic acids and utilities
EP2004800B1 (de) 2006-04-04 2014-01-15 Henry Morris Krisch Verfahren zur herstellung von bakteriophagenzusammensetzungen sowie verfahren auf dem gebiet der phagentherapie
KR100781669B1 (ko) 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
KR100759988B1 (ko) 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
GB0704553D0 (en) * 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
US7622293B2 (en) * 2007-06-18 2009-11-24 Intralytix, Inc. Pseudomonas aeruginosa: bacteriophage and uses thereof
US8734718B2 (en) 2007-08-17 2014-05-27 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US8366652B2 (en) * 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US9005263B2 (en) 2007-08-17 2015-04-14 The Invention Science Fund I, Llc System, devices, and methods including actively-controllable sterilizing excitation delivery implants
KR100910961B1 (ko) 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
JP5639475B2 (ja) 2007-11-27 2014-12-10 アルギファルマ アイピーアール エーエス バイオフィルムと闘う際のアルギネートオリゴマーの使用
US8153119B2 (en) * 2007-12-18 2012-04-10 Trustees Of Boston University Engineered enzymatically active bacteriophage and methods for dispersing biofilms
WO2009137136A2 (en) * 2008-02-15 2009-11-12 Trustees Of Boston University In vivo gene sensors
AU2009319659A1 (en) * 2008-11-28 2011-07-14 Jonathan J. Dennis Bacteriophage compositions for treatment of bacterial infections
US20110160681A1 (en) * 2008-12-04 2011-06-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including catheters having light removable coatings based on a sensed condition
US20110208021A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
US20110208026A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
US20120041286A1 (en) 2008-12-04 2012-02-16 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including implantable devices with anti-microbial properties
US8377866B2 (en) 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
US8043613B2 (en) 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
JP5202763B2 (ja) 2009-06-03 2013-06-05 アルギファルマ エーエス アルギネートオリゴマーと抗生物質とによるアシネトバクター感染の治療
CA2806559C (en) * 2009-09-02 2018-06-26 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
EP2465926A1 (de) * 2010-12-20 2012-06-20 University College Cork Pseudomonas aeruginosa-Bakteriophage und Verwendungen davon
AU2012279209A1 (en) * 2011-07-01 2014-01-23 Synedgen, Inc. Methods and compositions of reducing and preventing bacterial growth and the formation of biofilm on a surface utilizing chitosan-derivative compounds
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
WO2014059313A1 (en) 2012-10-12 2014-04-17 Lehigh University Thermally stable enzymes, compositions thereof and methods of using same
DE102013106455A1 (de) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Verfahren zur Dekontamination von bakteriologischen Verunreinigungen
JP2017524344A (ja) 2014-06-06 2017-08-31 ザ・ホスピタル・フォー・シック・チルドレンＴｈｅ Ｈｏｓｐｉｔａｌ Ｆｏｒ Ｓｉｃｋ Ｃｈｉｌｄｒｅｎ バイオフィルムの阻害及び分散における可溶性細菌及び真菌タンパク質並びに方法並びにそれらの使用
KR20170094121A (ko) 2014-09-11 2017-08-17 시너드젠, 인크. 조성물 및 그의 사용 방법
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2017211737A1 (fr) 2016-06-08 2017-12-14 Onelife S.A. Composition comprenant au moins une enzyme et au moins une molécule microbicide pour la prévention ou le traitement des infections post-implantatoires
EP3801029A4 (de) 2018-05-30 2022-03-09 Morehouse School of Medicine Antibakterielle zusammensetzungen, verfahren zur herstellung und verwendung davon
CA3227846A1 (en) * 2021-08-02 2023-02-09 Armata Pharmaceuticals, Inc. Bacteriophages with improved antimicrobial activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678750A (en) * 1984-10-18 1987-07-07 Microlife Technics, Inc. Method and compositions for use in the treatment of fireblight
US5032574A (en) 1988-05-26 1991-07-16 Invitron Corporation Novel antimicrobial peptide
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
WO1993024513A1 (en) * 1992-05-22 1993-12-09 The Children's Hospital Of Philadelphia Gastrointestinal defensins, cdna sequences and method for the production and use thereof
US5582825A (en) * 1993-02-24 1996-12-10 Gunze Limited Therapeutic medicine for cystic fibrosis
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
EP0895534A1 (de) * 1996-04-15 1999-02-10 Nymox Corporation Bakteriophagen enthaltende zusammensetzungen und methoden zur verwendung von bakteriophagen zur behandlung von infektionen
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
EP0925756B8 (de) * 1997-12-25 2008-08-13 Nihon Kohden Corporation Gerät zur Übertragung von biologischen Signalen
WO2002007742A2 (en) 2000-07-25 2002-01-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage having multiple host range

Also Published As

Publication number Publication date
DE602004022506D1 (de) 2009-09-24
GB0300597D0 (en) 2003-02-12
EP1587520B1 (de) 2009-08-12
US20060140911A1 (en) 2006-06-29
WO2004062677A1 (en) 2004-07-29
US7758856B2 (en) 2010-07-20
EP1587520A1 (de) 2005-10-26
WO2004062677A9 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
ATE439139T1 (de) Bakteriophage zur behandlung von bakteriellen biofilmen
ATE534372T1 (de) Verfahren und zusammensetzungen zur behandlung und prävention von infektionen
ATE524195T1 (de) Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
ATE513551T1 (de) Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora
ATE481134T1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
AU2001278003A1 (en) Bacteriophage having multiple host range
TW200734344A (en) Antibacterial agents
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
NZ595252A (en) Biofilm treatment
ATE427116T1 (de) Behandlung von bakteriellen infektionen
NO20083245L (no) Sykliske antimikrobielle peptider
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
MX2022006109A (es) Derivados 1-aminosulfonil-2-carboxipirrol como inhibidores de metalo-beta-lactamasa.
ATE296536T1 (de) Nichttoxische beschichtungszusammensetzung, verwendungsverfahren und gegen die anlagerung von biofouling-organismen behandelte gegenstände
RS52511B (en) MACHINE DISINFECTION OF ITEMS
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
AR029544A1 (es) Composiciones y metodos para tratar infecciones bacterianas
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE482705T1 (de) Antibakterielle behandlung von osteoarthritis
DK1439840T3 (da) Antibakterielle monobactam-forbindelser og fremgangsmåder til anvendelse heraf
DE60331781D1 (de) Verwendung von synergistischen lytischen enzymen aus bakteriophagen zur vorbeugung und behandlung bakterieller infektionen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties